CRISPR Therapeutics (CRSP) reported earnings of $1.10 per share for the fourth quarter of 2023 against the Zacks Consensus Estimate of a loss of 40 cents. In the year-ago period, the company had incurred a loss of $1.41 per share.The positive result was driven by collaboration revenue received from Vertex (VRTX) in connection with the approval of Casgevy (exagamglogene autotemcel [exa-cel]) for two blood disorder indications. Shares of CRSP rose 4.7% on Feb 21 as investors cheered the encouraging financial ...

Ole_CNXCRISPR Therapeutics (NASDAQ:CRSP), a leader in the gene-editing revolution, has captivated the attention of scientists and investors alike and received much attention from investors like Cathy Wood. Over the past five years, the company has been on a rollercoaster ride with explosive growth, going from a promising scientific tool to a reality with tangible therapeutic applications. Dramatic breakthroughs, regulatory approvals, and, of course, volatile price movements have marked this journey. So, ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Citi 2024 Virtual Oncology Leadership Summit Conference February 21, 2024 1:00 PM ET Company Participants Samarth Kulkarni - Chairman and Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citigroup Yigal Nochomovitz All right. Welcome back, everyone, to the next session of Citi's Virtual Oncology Leadership Summit. I'm Yigal Nochomovitz, one of the biotech analysts here at Citigroup. Remember if you have questions for Sam Kulkarni, the CEO of CRISP ...

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results — CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70, respectively – — Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a), respectively — — Clinical trial ...

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation rece ...

Cathie Wood's success is based on two main things: finding innovators and betting on them for the long term. The founder and chief executive officer of Ark Invest goes for innovators in all areas, from information technology to healthcare, and this helped her flagship Ark Innovation fund outperform the S&P 500 Index by a mile last year. Ark Innovation soared 67%, which the benchmark index advanced 24%.One of Wood's favorite technologies, in the area of healthcare, is gene editing, and last week, she increas ...

Cathie Wood stocks make headlines for their potential to be at the leading edge of disruptive technologies and generate high returns. Yet, Wood’s flagship ARK Innovation ETF (NYSEARCA:ARKK) has declined 8% year-to-date (YTD). On the other hand, the S&P 500 and Nasdaq 100 have gained 3.9% and 4.6%, respectively. Now, several of her portfolio companies present potentially appealing entry points for buy-and-hold investors, given their more attractive valuations.In her search for bargains, Wood recently added t ...

CRISPR Therapeutics AG (CRSP) shares rallied 6.9% in the last trading session to close at $84.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 29.9% gain over the past four weeks.Earlier this week, the company announced that the European Commission has granted conditional marketing authorization to Casgevy for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in pa ...

ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, February 21, 2024, at 1:00 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's w ...

CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they m ...